Loss of domestic producers of coenzyme Q10 Why Changing Faces – coenzyme, medicine, medicine – PHA

year 2006, which lasted a sudden change of face, coenzyme Q10, the export price from $ 2,700 / kg high dive 700 USD / kg, the price has dropped by almost 3 / 4 This loss transfer to domestic producers, Jiaokubudie, caught in a dilemma. Coenzyme Q10 each market suddenly became hostile? Such as culture species of national pharmaceutical ingredients, coenzyme Q10 in the development of future concern. The global supply and an imbalance in the submission of the application of non-specific immunostimulants coenzyme Q10 is involved in cellular metabolism and the process of cellular respiration. Resistant clinical disease of the coronary arteries, increased cardiac output, anti-arrhythmia, hypertension and other effects. The worsening of medical research in recent years, people have pharmacological coenzyme Q10, there are many new discoveries, such as myocardial protection improved internal coenzyme, trapping free radicals, maintaining the integrity of calcium channels to improve mitochondrial respiration and so on. The expansion Coenzyme Q10 function fields of application, so that demand is growing slowly. As the growth in demand faster than production, coenzyme Q10 is also climbing higher and higher prices in world markets as high as 3,000 to $ 4,000 / kg. 2005, world consumption of coenzyme Q10 has reached more than 300 tons, the consumption of functional foods represent about 60%, 20% of the drug, cosmetics and consumer accounts for 8%. In the U.S., Europe, Australia and other places, coenzyme Q10, health foods and slimming foods hot, there are statistics that show that coenzyme Q10 in the United States in recent years, the rate of market growth annual 15% to 20%. Coenzyme Q10 API China has to rely on Japanese imports, domestic demand is now about 20 tons. China coenzyme Q10 on demand is also increasing, in 2010, the annual global demand will reach 500 tons, the annual consumption in China will reach 60 tons. Domestic producers to compete to be launched to break the old patterns that foreign demand well, despite the production of coenzyme essential to supply the export of bulk drugs Q10, but still failed to fill the great void. Strong demand for the development of many companies in our countries competing coenzyme Q10. Coenzyme Q10 production solanesol important synthesis and microbial fermentation, most Chinese companies training solanesol. Solanesol tobacco waste as raw materials are extracted and China is a major tobacco states of growth, solanesol is the world’s production capacity of large countries. This provides a convenient domestic producers. 1999, the first Chinese production of coenzyme Q10 synthesis production line solanesol in Haimen, Jiangsu Communications Co., Ltd., with an annual production capacity of 10 tonnes. In 2003, Yunnan Lu Chase Liangyu, Biological Industry Co., Ltd. has successfully developed tobacco as raw material for waste coenzyme Q10 in technology and to build a road with independent intellectual property rights of production lines industry, the annual capacity of 5 tons. Xi’an Haotian biotechnology companies for the production of coenzyme Q10 and training of a certain size, most of the products purchased by foreign buyers directly. In 2005, Henan Topfond pharmaceutical production of semi-formation of coenzyme Q10, began producing a line of annual output of 5 tons. In addition, double Jinan Cheng Department of Taizhou, Zhejiang, opening the chemical and chemical companies also preparing a project on coenzyme Q10. The Fudan University, Shanghai developed synthesis of coenzyme Q10 production test data has been moved to a new synthetic drug company in Zhejiang, the company put into service in the near future. Many national companies have set coenzyme Q10, time significantly increased our production of coenzyme Q10, shattering the current market structure has led to the apprehension of foreign producers.

Tags: process of cellular respiration

Posted in Medicine